NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$82.44
-1.36 (-1.62%)
At Close: May 03, 2024
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 Update
04:49am, Monday, 06'th Jun 2022 Seeking Alpha
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.
Is Now the Time to Buy This Risky Stock With Huge Upside Potential?
03:07pm, Saturday, 04'th Jun 2022 The Motley Fool
Having a small drug development pipeline is a big risk, but it also leaves the door open potentially for big gains.
Is Now the Time to Buy This Risky Stock With Huge Upside Potential?
11:07am, Saturday, 04'th Jun 2022
Having a small drug development pipeline is a big risk, but it also leaves the door open potentially for big gains.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
06:25pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
03:48pm, Wednesday, 01'st Jun 2022
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
03:24pm, Friday, 27'th May 2022 Zacks Investment Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
12:48pm, Friday, 27'th May 2022
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin: A Good Anchor For Your Biotech Portfolio
01:13pm, Tuesday, 10'th May 2022
In a down market, you can pick up the same fundamentally robust companies at a fraction of their intrinsic value. As an orphan disease innovator, BioMarin is enjoying significant and substantial reven
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
03:04pm, Monday, 02'nd May 2022 Zacks Investment Research
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
12:34pm, Monday, 02'nd May 2022 Zacks Investment Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
04:33pm, Friday, 29'th Apr 2022 Zacks Investment Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
06:35pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
04:30pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
03:48pm, Thursday, 28'th Apr 2022
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2022 Results - Earnings Call Transcript
10:06pm, Wednesday, 27'th Apr 2022
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President, Investor Relations J.J. Bienaime - Chairman
